


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-10.54%
-2.53%
+9.81%
-25.94%
-1.69%
EBS
Emergent Biosolution
$12.42
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Risk Analysis

Investors losing their confidence
EBS Price Performance
$10.03 (+23.83%)
$8.74 (+42.11%)
$6.07 (+104.61%)
$10.32 (+20.35%)
EBS has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

EBS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
EBS Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EBS Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
CING
3.97
+2.85%
VKTX
35.19
+3.65%
SNY
48.18
+0.40%
COCP
0.99
-1.00%
VTRS
11.93
-0.08%
What is EBS current stock price?
What are EBS stock strengths?
What is EBS Risk Level?
What is EBS market cap and volume?
What is EBS current Stock IQ?
Should I buy EBS stock right now?
Is EBS a Strong Buy right now?
What does a 'Strong Buy' rating mean for EBS?
What does a 'Strong Sell' rating mean for EBS?
What factors influence EBS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-10.54%
-2.53%
+9.81%
-25.94%
-1.69%
EBS
Emergent Biosolution
Current Price
$12.42
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Risk Analysis

Investors losing their confidence
Linked to EBS
CING
3.97
+2.85%
VKTX
35.19
+3.65%
SNY
48.18
+0.40%
COCP
0.99
-1.00%
VTRS
11.93
-0.08%

EBS Price Performance
$10.03 (+23.83%)
$8.74 (+42.11%)
$6.07 (+104.61%)
$10.32 (+20.35%)
EBS Analysts Opinion
EBS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
EBS Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EBS Street Sentiment is extremely bullish and have positive views on the near-term outlook
EBS has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
EBS Stock IQ
EBS Latest Analysis
HC Wainwright & Co. Reiterates Emergent BioSolutions (EBS) Buy Recommendation. Fintel reports that on December 16 2025 HC Wainwright &. Co. reiterated coverage of Emergent BioSolutions (NYSE:EBS) with a Buy recommendation. Analyst Price Forecast Suggests 11.68% Upside
Tue Dec 16, 2025
MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD. By Business UpdateNew Data from Phase 2a Trial of Vanoglipel (DA-1241) Presented at The Liver Meeting 2025In November 2025 MetaVia Inc. (NASDAQ:MTVA) announced new data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented in a poster session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. A copy of the poster can be found .Vanoglipel is a potent and selective agonist for G p
Thu Dec 11, 2025
Tiny Biotech Terns Takes Aim At Novartis Leukemia Blockbuster. ) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated patients at the American Society of Hematology Annual Meeting and Exposition.As of the cutoff date of September 13 2025 63 patients were enrolled.Of 38 efficacy-evaluable patients the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks with 64% (18/28) achieving MMR and 100% .Also Read: D
Tue Dec 9, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.